An experimental antiviral developed by Chimerix Inc., Brincidofovir, received fast track designation from the US Food and Drug Administration (FDA) on 6 October. Under the Emergency Investigational New Drug Application, patients with Ebola can receive the drug. The first patient diagnosed with Ebola in the US reportedly received Brincidofovir treatment in Dallas, Texas. He died of his infection. 
